Physician profile
Rebeka Brouillard
NPI 1063172724
$2,952.13
in general payments reported to CMS, 2019-2025
24 companies · $965 in 2025
The $965 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $589 · 2023: $447 · 2024: $951 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $563.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $309.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.86 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $266.91 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $241.44 | 2022-2025 | |
| Amgen INC. | $234.66 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $181.33 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.59 | 2022-2025 | |
| Glaxosmithkline, LLC. | $130.32 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $125.29 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Idorsia Pharmaceuticals US INC | $97.60 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $79.11 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $72.29 | 2022-2024 | Rexulti |
| Baxter Healthcare | $26.19 | 2022 | |
| Almatica Pharma LLC | $21.19 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.64 | 2025 | Veozah |
| Lundbeck LLC | $19.98 | 2023 | Rexulti |
| Corcept Therapeutics | $19.08 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $18.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.50 | 2022 | |
| Currax Pharmaceuticals LLC | $16.51 | 2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.89 | 2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $15.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeka Brouillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.